Lilly (nyse: LLY - news - people ), which built a powerful presence in psychiatric drugs first with its now off-patent Prozac and now with antipsychotic Zyprexa, is following suit with what appears to be an even broader system for disclosing data.

FORBES: Silver Lining In Drug Disclosure